Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 9:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 352 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Invasive Breast Carcinoma Clear all
Recruiting Phase 2 Interventional

IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases

NCT06092892
View directory record Official record
Conditions
Breast Cancer, Axillary Nodal Disease, Female Breast Cancer, Axilla; Breast, Mastectomy; Lymphedema, Tumor, Breast
Interventions
Breast Surgery (BCS or mastectomy) with TAD/SNB, Adjuvant Radiation Therapy
Procedure · Radiation
Lead sponsor
Alice Chung
Other
Eligibility
45 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
3
States / cities
Los Angeles, California • Pasadena, California • Tarzana, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 30, 2026, 9:10 AM EDT
Completed Not applicable Interventional

MindVybe tVNS/APS for Wellbeing in Breast Cancer Survivors

NCT07782866
View directory record Official record
Conditions
Breast Cancer
Interventions
Transcutaneous vagus nerve and acupuncture point stimulation
Device
Lead sponsor
The Healing Consciousness Foundation
Other
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Meadowbrook, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 30, 2026, 9:10 AM EDT
Completed Phase 2 Interventional Results available

Volumetric Specimen Imager Device for the Intraoperative Imaging of Patients With Breast Carcinoma and Breast Ductal Carcinoma In Situ, The VIVID Study

NCT05545150
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Bilateral Breast Carcinoma, Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma, Prognostic Stage 0 Breast Cancer AJCC v8
Interventions
Intraoperative Imaging, Lumpectomy
Procedure · Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Chicago, Illinois • Lexington, Kentucky • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 30, 2026, 9:10 AM EDT
Completed Phase 3 Interventional Results available

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

NCT00538850
View directory record Official record
Conditions
Cancer
Interventions
Fentanyl sublingual spray, Placebo
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chandler, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Sep 30, 2026, 9:10 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

NCT04622319
View directory record Official record
Conditions
HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
Interventions
DS-8201a, T-DM1
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
126
States / cities
Anaheim, California • Baldwin Park, California • Bellflower, California + 94 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Sep 30, 2026, 9:10 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

NCT04448886
View directory record Official record
Conditions
Invasive Breast Cancer, Metastatic Breast Cancer, HR-Positive Breast Cancer, HER2-negative Breast Cancer
Interventions
Pembrolizumab, Sacituzumab Govitecan
Drug
Lead sponsor
Ana C Garrido-Castro, MD
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
8
States / cities
Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Sep 30, 2026, 9:10 AM EDT
Completed No phase listed Observational

Fast Spectral Imaging Device for Tumor Margin Mapping

NCT01107080
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Sep 30, 2026, 9:10 AM EDT
Recruiting Not applicable Interventional

Novel Cavity Marking Technique in Breast Cancer Patients Undergoing Breast Conservation Surgery With Oncoplastic Reconstruction for the Delivery of Adjuvant Radiotherapy and Accuracy of Recommended Re-excisions

NCT06903468
View directory record Official record
Conditions
Ductal Carcinoma in Situ, Breast Cancer
Interventions
Novel cavity marking technique
Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 30, 2026, 9:10 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer

NCT02448771
View directory record Official record
Conditions
Breast Cancer Stage IV, Unresectable Locally Advanced Invasive Breast Cancer, Metastatic Invasive Breast Cancer
Interventions
Palbociclib, Bazedoxifene
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Sep 30, 2026, 9:10 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Fluorine-18 3'-Deoxy-3'-Fluorothymidine (F-18-FLT) in Invasive Breast Cancer

NCT00572728
View directory record Official record
Conditions
Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
CT, 18F-FLT, PET
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
27
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2016 · Synced Sep 30, 2026, 9:10 AM EDT
Recruiting Phase 2 Interventional

Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients

NCT04677816
View directory record Official record
Conditions
Triple Negative Breast Cancer, Vitamin D Deficiency, Invasive Breast Cancer
Interventions
Standard of Care Neoadjuvant Chemotherapy (NAC), Vitamin D3, Drug Diary
Drug · Dietary Supplement · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Sep 30, 2026, 9:10 AM EDT
Completed Phase 2 Interventional Results available

Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer

NCT02530489
View directory record Official record
Conditions
Breast Adenocarcinoma, Invasive Breast Carcinoma, Triple-Negative Breast Carcinoma
Interventions
Atezolizumab, Nab-paclitaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 30, 2026, 9:10 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Blood Sample Collection and Health Information Collection From Patients With Invasive Breast Cancer and Their Brothers and Sisters

NCT00445562
View directory record Official record
Conditions
Breast Cancer
Interventions
biologic sample preservation procedure, informational intervention
Other
Lead sponsor
GenBasix Incorporated
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2001
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Sep 30, 2026, 9:10 AM EDT
Completed No phase listed Observational

X-Ray Mammography Standard of Care Protocol

NCT01052740
View directory record Official record
Conditions
Breast Cancer, Invasive Carcinoma, In Situ Carcinoma, Fibrocystic Changes, Atypical Ductal Hyperplasia
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 100 Years · Female only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Sep 30, 2026, 9:10 AM EDT
Active, not recruiting Phase 2 Interventional

SHORTened Duration of TAMoxifen

NCT07806630
View directory record Official record
Conditions
High Risk for Invasive Breast Cancer
Interventions
Tamoxifen, Tamoxifen (Nolvadex)
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
30 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 30, 2026, 9:10 AM EDT
Recruiting Phase 2 Interventional

Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

NCT02422641
View directory record Official record
Conditions
Metastatic Breast Cancer, Leptomeningeal Disease
Interventions
High-dose Methotrexate (8 gm/m2; HD-MTX)
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
3
States / cities
Baltimore, Maryland • St Louis, Missouri • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Sep 30, 2026, 9:10 AM EDT
Completed Not applicable Interventional

Selective Image Guided Resection of Axillary Lymph Nodes

NCT01880645
View directory record Official record
Conditions
Breast Cancer
Interventions
Fine Needle Aspiration (FNA), Ultrasound, Breast Surgery + Lymph Node Removal
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2015 · Synced Sep 30, 2026, 9:10 AM EDT
Completed Phase 3 Interventional Results available

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

NCT01275677
View directory record Official record
Conditions
HER2/Neu Positive, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Interventions
Cyclophosphamide, Docetaxel, Doxorubicin, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment, Trastuzumab
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
3,270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
1259
States / cities
Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 797 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Sep 30, 2026, 9:10 AM EDT
Completed Phase 1 Interventional

Capecitabine and Radiotherapy in the Adjuvant Treatment of Resistant Breast Cancer

NCT03958721
View directory record Official record
Conditions
Resistant Breast Cancer, Non-metastatic Invasive Breast Cancer
Interventions
Capecitabine, Radiotherapy
Drug · Radiation
Lead sponsor
A Bapsi Chakravarthy, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Sep 30, 2026, 9:10 AM EDT
Completed Not applicable Interventional Results available

BrUOG 291: Five Fraction Partial Breast Irradiation Using Non-invasive Image-guided Breast Brachytherapy (NIBB)

NCT01961531
View directory record Official record
Conditions
Breast Cancer
Interventions
Accuboost APBI
Device
Lead sponsor
Brown University
Other
Eligibility
50 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
3
States / cities
La Jolla, California • Lakeland, Florida • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 4, 2022 · Synced Sep 30, 2026, 9:10 AM EDT
Completed Not applicable Interventional

A Home-Based Walking Program and rTMS in Helping Breast Cancer Survivors Get More Physical Activity

NCT03789877
View directory record Official record
Conditions
Cancer Survivor, Invasive Breast Carcinoma
Interventions
Physical Activity, Questionnaire Administration, Repetitive Transcranial Magnetic Stimulation, Sham Intervention
Other · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 64 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Sep 30, 2026, 9:10 AM EDT
Completed Not applicable Interventional

Delayed-Delayed Breast Reconstruction

NCT01256528
View directory record Official record
Conditions
Breast Cancer
Interventions
Delayed Breast Reconstruction
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2016 · Synced Sep 30, 2026, 9:10 AM EDT
Completed Phase 1 Interventional

Radiation Therapy Using Gold Markers in Treating Women With Early-Stage Breast Cancer

NCT00749437
View directory record Official record
Conditions
Breast Cancer
Interventions
3-dimensional conformal accelerated partial breast irradiation
Radiation
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
45 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 14, 2012 · Synced Sep 30, 2026, 9:10 AM EDT
Completed No phase listed Observational

Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer

NCT01706432
View directory record Official record
Conditions
Central Nervous System Metastases, Invasive Ductal Breast Carcinoma, Invasive Ductal Breast Carcinoma With Predominant Intraductal Component, Invasive Lobular Breast Carcinoma, Invasive Lobular Breast Carcinoma With Predominant in Situ Component, Liver Metastases, Lobular Breast Carcinoma in Situ, Lung Metastases, Male Breast Cancer, Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate, Mucinous Ductal Breast Carcinoma, Papillary Ductal Breast Carcinoma, Recurrent Breast Cancer, Stage IV Breast Cancer, Tubular Ductal Breast Carcinoma, Tumors Metastatic to Brain
Interventions
hyperfractionated radiation therapy, laboratory biomarker analysis, stereotactic radiosurgery
Radiation · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2024
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Sep 30, 2026, 9:10 AM EDT